These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 17639393)
1. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Meng F; Cai X; Duan J; Matteucci MG; Hart CP Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393 [TBL] [Abstract][Full Text] [Related]
2. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708 [TBL] [Abstract][Full Text] [Related]
3. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Nathwani SM; Butler S; Fayne D; McGovern NN; Sarkadi B; Meegan MJ; Lloyd DG; Campiani G; Lawler M; Williams DC; Zisterer DM Cancer Chemother Pharmacol; 2010 Aug; 66(3):585-96. PubMed ID: 20020128 [TBL] [Abstract][Full Text] [Related]
4. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2. Combes S; Barbier P; Douillard S; McLeer-Florin A; Bourgarel-Rey V; Pierson JT; Fedorov AY; Finet JP; Boutonnat J; Peyrot V J Med Chem; 2011 May; 54(9):3153-62. PubMed ID: 21488686 [TBL] [Abstract][Full Text] [Related]
6. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells. Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672 [TBL] [Abstract][Full Text] [Related]
7. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Bacher G; Nickel B; Emig P; Vanhoefer U; Seeber S; Shandra A; Klenner T; Beckers T Cancer Res; 2001 Jan; 61(1):392-9. PubMed ID: 11196193 [TBL] [Abstract][Full Text] [Related]
8. Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents. Kim ND; Park ES; Kim YH; Moon SK; Lee SS; Ahn SK; Yu DY; No KT; Kim KH Bioorg Med Chem; 2010 Oct; 18(19):7092-100. PubMed ID: 20810285 [TBL] [Abstract][Full Text] [Related]
9. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459 [TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors. Cao D; Liu Y; Yan W; Wang C; Bai P; Wang T; Tang M; Wang X; Yang Z; Ma B; Ma L; Lei L; Wang F; Xu B; Zhou Y; Yang T; Chen L J Med Chem; 2016 Jun; 59(12):5721-39. PubMed ID: 27213819 [TBL] [Abstract][Full Text] [Related]
11. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006 [TBL] [Abstract][Full Text] [Related]
13. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674 [TBL] [Abstract][Full Text] [Related]
14. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798 [TBL] [Abstract][Full Text] [Related]
15. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). Shen H; Lee FY; Gan J J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: Potent inhibitors of angiogenesis and tubulin polymerization. Sun M; Zhang Y; Qin J; Ba M; Yao Y; Duan Y; Liu H; Yu D Bioorg Chem; 2021 Aug; 113():104988. PubMed ID: 34034135 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities. Zhang H; Fang X; Meng Q; Mao Y; Xu Y; Fan T; An J; Huang Z Eur J Med Chem; 2018 Sep; 157():380-396. PubMed ID: 30099258 [TBL] [Abstract][Full Text] [Related]
18. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells. Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540 [TBL] [Abstract][Full Text] [Related]
19. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo. Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592 [TBL] [Abstract][Full Text] [Related]
20. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity. Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]